购物车
- 全部删除
- 您的购物车当前为空
SU3327 (halicin) 是具有底物竞争性的 JNK 选择性抑制剂,IC50为 0.7 μM。它还抑制 JNK 和 JIP 之间的蛋白相互作用,IC50值为 239 nM。
为众多的药物研发团队赋能,
让新药发现更简单!
SU3327 (halicin) 是具有底物竞争性的 JNK 选择性抑制剂,IC50为 0.7 μM。它还抑制 JNK 和 JIP 之间的蛋白相互作用,IC50值为 239 nM。
规格 | 价格 | 库存 | 数量 |
---|---|---|---|
1 mg | ¥ 247 | 现货 | |
2 mg | ¥ 359 | 现货 | |
5 mg | ¥ 622 | 现货 | |
10 mg | ¥ 969 | 现货 | |
25 mg | ¥ 1,620 | 现货 | |
50 mg | ¥ 2,420 | 现货 | |
100 mg | ¥ 3,580 | 现货 | |
1 mL x 10 mM (in DMSO) | ¥ 625 | 现货 |
产品描述 | SU3327 (halicin) is a potent, selective and substrate-competitive inhibitor of JNK(IC50 of 0.7 μM). |
靶点活性 | JNK-JIP:239 nM , JNK:0.7 μM |
体外活性 | TNF-α stimulated phosphorylation of c-Jun in HeLa cells inhibited by SU3327 with EC50 of 6.23 μM[1]. SU3327 (25 nM) pretreatment of human-derived cerebral microvascular endothelial cells (hCMEC/D3) effectively reduces LPS-induced polymorphonuclear leukocytes (PMN) rolling/adhesion to hCMEC/D3, prevents activation of AP-1, and significantly reduces expression of VCAM-1[3]. |
体内活性 | In male BKS.Cg-+Leprdb/+Leprdb/OlaHsd db/db mice, SU3327 (25 mg/kg; intraperitoneal injection; ) treatment possesses the ability to restore insulin sensitivity in mice models of diabetes[1]. SU3327 has favorable microsomal and plasma stability (T1/2 = 27 min)[1]. |
别名 | halicin |
分子量 | 261.3 |
分子式 | C5H3N5O2S3 |
CAS No. | 40045-50-9 |
Smiles | Nc1nnc(Sc2ncc(s2)[N+]([O-])=O)s1 |
密度 | 1.888g/cm3 |
存储 | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. | |||||||||||||||||||||||||||||||||||
溶解度信息 | DMSO: 62.5 mg/mL (239.19 mM), Sonication is recommended. | |||||||||||||||||||||||||||||||||||
溶液配制表 | ||||||||||||||||||||||||||||||||||||
DMSO
|
版权所有©2015-2024 TargetMol Chemicals Inc.保留所有权利.
评论内容